Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
Please join us for an ECHO webinar on Tuesday June 15, 2021 (11 am – 12 pm EST) featuring Dr. Gavin Oudit (Founder & Chief Operating Officer, PEARKO Therapeutics Inc.; Professor, Department of Medicine, University of Alberta; Clinician-Scientist, Mazankowski Alberta Heart Institute; Director, Heart Function Clinic; Canada Research Chair in Heart Failure).
Dr. Oudit’s presentation entitled, “Apelin Analogs as Novel Biologics for Cardiovascular Disease”, will feature an overview of PEARKO Therapeutics, its technologies and the story behind its success. PEARKO Therapeutics is a biopharmaceutical company engaged in the practice of translational medicine: catalyzing and driving the translation of molecular discoveries to patients. PEARKO Therapeutics has established itself in the field of cardiovascular medicine with its highly effective and highly versatile biologic: apelin analog therapy.
Register in advance for this meeting: https://us02web.zoom.us/meeting/register/tZcqc-GqqjIiH9XHnsx3G6KM0FXUTbmBcfTH
After registering, you will receive a confirmation email containing information about joining the webinar.
ECHO is an entrepreneurship training program, funded and organized in a partnership between (i) the Translational Biology and Engineering Program (TBEP), the University of Toronto component of the Ted Rogers Centre for Heart Research, and (ii) the Health Innovation Hub (H2i).
